Analysis of the clinical effect of Anlotinib hydrochloride capsules in the treatment of advanced non-small cell lung cancer patients

Abstract

Objective To observe the curative effects and toxic side effects of Anlotinib hydrochloride capsules in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Clinical data was collected from 35 patients who were diagnosed of phase ⅢB to Ⅳ advanced NSCLC and were treated with Anlotinib hydrochloride capsules during June 2018 to March 2019 in Changhai Hospital Affiliated to Naval Medical University.All these patients had been treated with one or two lines of standard prior treatments and the follow-up time was cut off until March 31st, 2019. Results No case achieved complete response or partial response, 19 cases (54.3%)achieved stable disease and 16(45.7%) achieved progressive disease in 35 cases.The ORR was 0% and the DCR was 54.3%.The clinical effect was not related with the following factors including the mutation of EGFR and ROS1, the expression status of PD1, PDL1, p53 and KI67, gender, pathology type, stage, age and PS score.The median PFS of non-smoking group was higher than that of the smoking group [M(QR): 3.3(2.0) months vs 2.0(1.5) months] and the difference was statistically significant (Z=1.23, P<0.05). The median PFS of group with brain metastasis was lower than that of group without brain metastasis [M(QR): 3.7(2.9) months vs 6.5(2.0) months] and the difference was statistically significant (Z=-2.21, P<0.05). The median PFS of group with adverse reactions was higher than that of group without adverse reactions [M(QR): 3.6(1.9) months vs 2.3(1.7) months] and the difference was statistically significant (Z=-2.07, P<0.05). Adverse reactions included 4 cases of hypertension (11.42%), 6 case of hand-foot syndrome (17.14%), 5 case of gastrointestinal reaction (14.28%), 1 case of renal deficiency (2.85%), 1 case of pneumothorax (2.85%), 3 cases of oral ulcer (8.57%) and 4 cases of hoarseness (11.42%). Conclusions Anlotinib hydrochloride in the treatment of advanced NSCLC has certain therapeutic effect, which is superior in non-smoking patients, group without brain metastasis and patients suffering adverse reactions.The adverse reactions can be tolerated after symptomatic treatment.Anlotinib hydrochloride has special clinical application value in patients with advanced NSCLC. Key words: Carcinoma, non-small-cell lung; Treatment outcome; Anlotinib hydrochloride; Vascular endothelial growth factor-kinase inhibitor; Adverse reaction